Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon
about
CPU86017, a berberine derivative, attenuates cardiac failure through normalizing calcium leakage and downregulated phospholamban and exerting antioxidant activityIsoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213Isoproterenol-induced FKBP12.6/12 downregulation is modulated by ETA and ETB receptors and reversed by argirhein, a derivative of rheinRaisanberine protected pulmonary arterial rings and cardiac myocytes of rats against hypoxia injury by suppressing NADPH oxidase and calcium influxArgirein alleviates stress-induced and diabetic hypogonadism in rats via normalizing testis endothelin receptor A and connexin 43Sildenafil and FDP-Sr attenuate diabetic cardiomyopathy by suppressing abnormal expression of myocardial CASQ2, FKBP12.6, and SERCA2a in rats.Role of endothelin receptor A and NADPH oxidase in vascular abnormalities.CPUY11018, an azimilide derivative, ameliorates isoproterenol-induced cardiac insufficiency through relieving dysfunctional mitochondria and endoplasmic reticulum.Depressed calcium-handling proteins due to endoplasmic reticulum stress and apoptosis in the diabetic heart are attenuated by argirein.Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin.Exogenous hydrogen sulphide ameliorates diabetic cardiomyopathy in rats by reversing disordered calcium-handling system in sarcoplasmic reticulum.Comparison of sildenafil with strontium fructose diphosphate in improving erectile dysfunction against upregulated cavernosal NADPH oxidase, protein kinase Cε, and endothelin system in diabetic rats.
P2860
Q24567695-57951B9A-C8DB-44E4-9FD5-AFB0276E472BQ33552820-F9283700-9999-4B04-9FA8-25A5ECAA7167Q33565656-F98E45E3-FA3C-4A0C-BC74-EF7F4484D853Q33567412-2E9156B8-0C50-4051-BA7F-F0F04BDA8D2FQ36579278-43E3F1D6-3000-4841-95FF-6810903BCD8EQ37727411-7D25DED5-05FE-4011-9A6D-E3B55A8C6FE9Q37790995-9E2CE52D-2B37-4262-A360-90A438A3385BQ39199194-A47A8D19-56B0-4267-873E-B03EC3647E15Q44271787-16B9074F-9C68-41F5-B010-76625AE47909Q46030445-056EA172-3824-42BF-B060-091CB0AF7914Q46581242-A8CACE4A-6658-4693-A008-06257FA33E38Q54330771-790B9C90-755C-40A3-A623-2F4173A04287
P2860
Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon
description
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
im September 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2008/09/04)
@sk
vědecký článek publikovaný v roce 2008
@cs
wetenschappelijk artikel (gepubliceerd op 2008/09/04)
@nl
наукова стаття, опублікована у вересні 2008
@uk
مقالة علمية (نشرت في 4-9-2008)
@ar
name
Endothelin receptor antagonist ...... rphosphorylation of PKCepsilon
@ast
Endothelin receptor antagonist ...... rphosphorylation of PKCepsilon
@en
Endothelin receptor antagonist ...... rphosphorylation of PKCepsilon
@nl
type
label
Endothelin receptor antagonist ...... rphosphorylation of PKCepsilon
@ast
Endothelin receptor antagonist ...... rphosphorylation of PKCepsilon
@en
Endothelin receptor antagonist ...... rphosphorylation of PKCepsilon
@nl
prefLabel
Endothelin receptor antagonist ...... rphosphorylation of PKCepsilon
@ast
Endothelin receptor antagonist ...... rphosphorylation of PKCepsilon
@en
Endothelin receptor antagonist ...... rphosphorylation of PKCepsilon
@nl
P2093
P1476
Endothelin receptor antagonist ...... rphosphorylation of PKCepsilon
@en
P2093
P304
P356
10.1016/J.EJPHAR.2008.06.080
P407
P577
2008-09-04T00:00:00Z